Scholar Rock Holding Corporation (SRRK) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Cambridge, MA, United States. Der aktuelle CEO ist David L. Hallal.
SRRK hat IPO-Datum 2018-05-25, 128 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $5.69B.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on discovering and developing medicines that target protein growth factor signaling pathways to treat serious diseases. The company's lead candidate, Apitegromab, a myostatin activation inhibitor, has completed Phase 3 clinical trials for spinal muscular atrophy treatment, while SRK-181 is in Phase 1 development for checkpoint inhibitor-resistant cancers. Scholar Rock maintains a strategic collaboration with Gilead Sciences to develop transforming growth factor beta inhibitors for fibrotic diseases, with a broader pipeline addressing neuromuscular disorders, oncology, and fibrosis indications. Founded in 2012 and headquartered in Cambridge, Massachusetts, the company aims to transform patient outcomes across multiple serious disease areas through its targeted therapeutic approach.
